Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML)
DeAngleo DJ, Amrein PC, Kovacsovics TJ, Klisovic RB, Powell BL, Cooper M, Webb IJ, Stone RM. Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML). Blood. 2006; 108:51a.